Comparison between RIS group and SARC group in mRNA-seq and WES data. (A) Expression levels of IDO and CTLA-4 in the RIS group and SARC group in mRNA-seq. (B) The anti-tumor immunity score and the proliferation module score of the RIFS group and the RIOS group. (C) The comparison of the anti-tumor immunity score and the proliferation module score between subtypes RIFS vs FS and between RIOS vs OS. (D) Mutation summary of WES data in the RIS and SARC groups. (E) Top 50 mutated genes in RIFS, FS, RIOS and OS subtype groups.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: